The Quantitative Decision-making Special Interest Group (QDM SIG) was formed in October 2017. It is a group of statisticians from industry and academia, with experience and interests in statistical methods for quantitative decision-making in drug development. The objectives of the SIG are:
| Thomas Blondel (Ceva) |
| Nicolas Bonnet (Sanofi) |
| Daniel Bratton (GSK) |
| Sarah Bray (Amgen) |
| Alex Carlton (GSK) (Co-Chair) |
| Jacquie Christie (Sobi) |
| Paul Frewer (AstraZeneca) |
| Heiko Goette (Merck) |
| Tadhg Guerin (Theravance) (Co-Chair) |
| Kimberley Hacquoil (Exploristics) |
| Martin Johnson (UCB Pharma) |
| Kevin Kunzmann (Boehringer Ingelheim) |
| John-Philip Lawo (CSL Behring) |
| Daniel Leibovitz (Incyte) |
| Jesper Madsen (Novo Nordisk) |
| Pavel Mozgunov (Cambridge University) |
| Emmanuel Pham (Nova Discovery) |
| Gustaf Rydevik (UCB Pharma) |
| Gaëlle Saint-Hilary (Saryga) |
| Guido Thömmes (Merck) |
| Katie Thorn (GSK) |
| Stefano Vezzoli (Chiesi Farmaceutici) |
| Stig Johan Wiklund (Captario) |
| Corine Baayen (Lundbeck) |
Lasse Breuning Sluth (Lundbeck) |
Caroline Petit |
Gilles Guillot (CSL Behring) |
For further information, or to join the QDM SIG, please contact our Co-Chairs:
Alex Carlton (GSK) alex.l.carlton@gsk.com
Tadhg Guerin (Theravance) tguerin@theravance.com
